Valuation: NOVELSTEM

Market Cap 6L 5L 5L 4L 8L 5.39Cr 8L 54.09L 21.18L 2.69Cr 21.24L 20.77L 8.86Cr P/E 2024
-0.11x
P/E 2025 0.18x
Enterprise Value 24.69L 21.46L 20.03L 18.39L 34.68L 24Cr 35.28L 2.36Cr 92.51L 12Cr 92.73L 90.68L 39Cr EV / Sales 2024
39,81,32,333x
EV / Sales 2025 -
Free-Float
38.73%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Director of Finance/CFO 63 29/09/2022
President 67 13/01/2023
Director TitleAgeSince
Director/Board Member 66 -
Chairman 72 22/01/1993
Chairman 67 01/07/2018
Change 5-day change 1-year change 3-year change Capi.($)
+7.57%-3.50% - - 6L
+10.00%+13.39%+51.99%+83.45% 5.67TCr
+0.80%-5.70%+23.89%+62.65% 5.2TCr
+1.00%+0.95%-15.18%-12.35% 2.33TCr
+0.25%-4.82%-10.90%+350.70% 2.13TCr
+1.73%-1.57%+32.81%-25.80% 1.74TCr
+4.29%+1.67%+201.24%+344.48% 1.48TCr
+1.80%-0.85%+52.21%+176.42% 1.38TCr
+2.64%+3.07%+436.99%+179.35% 1.21TCr
+4.93%-6.61%+61.21%+158.72% 1.11TCr
Average +3.50%-0.63%+92.70%+146.40% 2.47TCr
Weighted average by Cap. +3.79%+0.44%+62.19%+117.70%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.02 1.14 0.02 0.11 0.04 0.57 0.05 0.04 1.88 -
Net income -32.33L -28.1L -26.23L -24.08L -45.41L -31Cr -46.2L -3.09Cr -1.21Cr -15Cr -1.21Cr -1.19Cr -51Cr 23.8L 20.68L 19.31L 17.73L 33.43L 23Cr 34.01L 2.28Cr 89.18L 11Cr 89.39L 87.41L 37Cr
Net Debt 44.12L 38.34L 35.8L 32.86L 61.97L 42Cr 63.05L 4.22Cr 1.65Cr 21Cr 1.66Cr 1.62Cr 69Cr 19.03L 16.54L 15.44L 14.18L 26.73L 18Cr 27.2L 1.82Cr 71.33L 9.05Cr 71.5L 69.91L 30Cr
Logo NOVELSTEM
NovelStem International Corp. is a development stage biotechnology holding company focused on stem cell-based technology. The Company's primary assets are NewStem Ltd (NewStem) and NetCo Partners (NetCo). NewStem focuses on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy. NewStem is principally focused on utilizing proprietary human Pluripotent Stem Cells (hPSCs) and Haploid human Pluripotent Stem Cells (HhPSCs) in the development of diagnostic and therapeutic products in oncology. Its NewStem Software Diagnostic Device (NSDD) is a bioinformatics-based software medical device platform that provides oncologists with information regarding the presence of mutations in tumors, which may confer patient resistance to certain anti-cancer drugs. NetCo is a media business interest which owns Net Force, a book publishing franchise.
Employees
-